Fragatou S.,Hospital G Gennimatas |
Tsourveloudis I.,Hospital G Gennimatas |
Manesis G.,Ippokration General Athens Hospital
Hemoglobin | Year: 2010
Hepatocellular carcinoma (HCC), following liver cirrhosis as a complication of chronic hepatitis B or C viruses (HBV or HCV)and iron overload, has been reported in thalassemia patients. This study assessed HCC incidences, the role of iron and possible antitumor activity of chelators in 57 thalassemia major (TM) and nine thalassemia intermedia (TI) patients using deferoxamine (DFO) therapy. Antibodies against HCV were detected in 2357 (40.4) TM patients, chronic HCV and cirrhosis were diagnosed in 1323 (56.5), 712 did not respond to antiviral therapy and 27 progressed to HCC (incidence 257, 3.5). Three (33.3) TI patients with liver siderosis and fibrosis and late introduction of iron chelation developed HCC without a history of hepatitis. The incidence was higher in TI (p 0.032). The main risk factor for HCC was HCV infection in TM patients but it was iron activity in TI patients. Iron chelation with DFO appeared to play a protective role. © 2010 Informa UK, Ltd.